John Mark O'Mahony Form 3 LEAP THERAPEUTICS / John Mark O'Mahony ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

O'Mahony John Mark

(Last)

(First)

(Middle)

C/O LEAP THERAPEUTICS, INC.

47 THORNDIKE STREET, SUITE B1-1

(Street)

CAMBRIDGE

02141

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2020

3. Issuer Name and Ticker or Trading Symbol
LEAP THERAPEUTICS, INC. [ LPTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Manufacturing Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	⁽¹⁾	12/05/2022	Common Stock	805	4.37	D
Employee Stock Option (Right to Buy)	⁽²⁾	01/23/2023	Common Stock	1,230	3.97	D
Employee Stock Option (Right to Buy)	⁽³⁾	09/08/2024	Common Stock	7,122	5.56	D
Employee Stock Option (Right to Buy)	⁽⁴⁾	09/11/2024	Common Stock	4,428	5.36	D
Employee Stock Option (Right to Buy)	⁽⁵⁾	01/19/2027	Common Stock	68,990	9.9	D
Employee Stock Option (Right to Buy)	⁽⁶⁾	01/22/2027	Common Stock	17,000	9.9	D
Employee Stock Option (Right to Buy)	⁽⁷⁾	11/28/2027	Common Stock	75,000	6.49	D
Employee Stock Option (Right to Buy)	⁽⁸⁾	04/17/2028	Common Stock	20,000	7.66	D
Employee Stock Option (Right to Buy)	⁽⁹⁾	12/04/2028	Common Stock	20,000	3.68	D
Employee Stock Option (Right to Buy)	⁽¹⁰⁾	06/10/2029	Common Stock	90,000	1.39	D
Employee Stock Option (Right to Buy)	⁽¹¹⁾	03/01/2030	Common Stock	150,000	2.94	D

Explanation of Responses:

1. The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan, 25% of which cliff vested and became exercisable on December 6, 2013 and the remainder of which vested and became exercisable in a series of 12 equal quarterly installments thereafter until the Option was fully vested.

2. The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan, 25% of which cliff vested and became exercisable on January 24, 2014 and the remainder of which vested and became exercisable in a series of 12 equal quarterly installments thereafter until the Option was fully vested.

3. The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan, 25% of which cliff vested and became exercisable on September 9, 2015 and the remainder of which vested and became exercisable in a series of 12 equal quarterly installments thereafter until the Option was fully vested.

4. The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan, 25% of which cliff vested and became exercisable on September 12, 2015 and the remainder of which vested and became exercisable in a series of 12 equal quarterly installments thereafter until the Option was fully vested.

5. The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan and fully vested and became exercisable on January 20, 2017, the date of grant.

6. The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan, with 25% cliff vesting and becoming exercisable on January 23, 2018 and the remainder vesting and becoming exercisable in a series of 36 equal monthly installments thereafter until the Option is fully vested.

7. The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 48 equal monthly installments until the Option is fully vested, with the first such installment vesting on December 29, 2017.

8. The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 48 equal monthly installments until the Option is fully vested, with the first such installment vesting on May 18, 2018.

9. The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 48 equal monthly installments until the Option is fully vested, with the first such installment vesting on January 5, 2019.

10. The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such installment vesting on July 11, 2019.

11. The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such installment vesting on April 2, 2020.

	/s/ Douglas E. Onsi	04/06/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

John Mark O'Mahony Form 3LEAP THERAPEUTICS / John Mark O'Mahony ownership change